TY  - JOUR
PY  - 2002//
TI  - Cognitive and behavioral effects of quetiapine in Alzheimer disease patients
JO  - Alzheimer disease and associated disorders
A1  - Scharre, Douglas W.
A1  - Chang, Shu-Ing
SP  - 128
EP  - 130
VL  - 16
IS  - 2
N2  - In a prospective, open-label, 12-week pilot study in outpatients with probable Alzheimer disease (AD) with psychosis or aggressive behaviors, we used the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and the Neuropsychiatric Inventory (NPI) to evaluate the cognitive and behavioral effects of quetiapine. After receiving doses ranging from 50 to 150 mg, patients given quetiapine showed a significant decrease of delusions, aggression, and overall behaviors based on NPI scores at 6 and 12 weeks. ADAS-cog scores did not show a significant change over 12 weeks. This study provides initial evidence that quetiapine does not significantly worsen cognition in AD outpatients.<p /> <p>Language: en</p>
LA  - en
SN  - 0893-0341
UR  - http://dx.doi.org/
ID  - ref1
ER  -